Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients

Depression Clinical Trial

Official title:

Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01718821
• Other study ID #: A-ER-101-134
• Status: Completed
• Phase: N/A
• First received: October 16, 2012
• Last updated: September 24, 2014
• Start date: September 2012
• Est. completion date: September 2014

Study information

• Verified date: September 2014
• Source: National Cheng Kung University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Observational

Clinical Trial Summary

Pain is one of the most common symptoms associated with cancer. The approach to pain management compresses routine pain assessments, utilizes both pharmacologic and nonpharmacologic interventions, and requires ongoing reevaluation of the patient. Cancer pain can be well controlled in the vast majority of patients if the algorithms of pain control are systematically applied, carefully monitored, and tailored to the needs of the individual patient.This study is aimed to assess the current pain managements in upper gastrointestinal cancer patients in Taiwan. The effects of neuropathic pain and depression on the enrolled patients would also be assessed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: September 2014
• Est. primary completion date: September 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• with a diagnose of advanced upper GI cancer based on pathology or imaging studies

• could report pain intensities and answer questionnaires by him/herself

Exclusion Criteria:

• with major neurologic or psychiatric diseases

• could not report pain intensities and answer questionnaires by him/herself

Study Design

Observational Model: Ecologic or Community, Time Perspective: Prospective

Related Conditions & MeSH terms

• Depression
• Gastrointestinal Neoplasms
• Neuralgia
• Neuropathic Pain
• Pain
• Quality of Life
• Upper GI Cancer

Locations

Country	Name	City	State
Taiwan	National Cheng Kung University Hospital	Tainan

Sponsors (1)

Lead Sponsor	Collaborator
National Cheng Kung University

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain, assessed by BPI-SF.	Pain intensities of participants would be assessed by BPI-SF at D1.	Assessed at enrolled date (Day 1)	No
Primary	Changes in pain, assessed by BPI-SF.	Changes in pain intensities of participants would be assessed by BPI-SF. The changes in pain would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.	Baseline and 1 month.	No
Secondary	Depression, assessed by two stem questions.	Depression of participants would be assessed by questionnaires as mentioned at D1.	Assessed at enrolled date (Day 1)	No
Secondary	Changes in depression, assessed by two stem questions.	Changes in depression status would be assessed by questionnaires as mentioned. The changes would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.	Baseline and 1 month.	No
Secondary	Quality of life, assessed by EROTC QLQ C30.	Quality of life of participants would be assessed by questionnaires as mentioned at D1.	Day 1	No
Secondary	Neuropathic pain, assessed by DN4 questions.	Neuropathic pain of participants would be assessed by questionnaires as mentioned at D1.	Day 1	No
Secondary	Changes in quality of life. Quality of life, assessed by EROTC QLQ C30.	Changes in quality of life would be assessed by questionnaires as mentioned. The changes would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.	Baseline and 1 month.	No
Secondary	Changes in neuropathic pain. Neuropathic pain, assessed by DN4 questions.	Changes in neuropathic pain would be assessed by questionnaires as mentioned. The changes would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.	Baseline and 1 month.	No